Filana Therapeutics’ FDA clinical hold on simufilam was lifted, clearing its planned proof-of-concept study and putting patient screening on track for the first quarter of 2027. The study is intended to produce data that guide simufilam’s development in TSC-related epilepsy and inform future research involving younger patients.

Key Highlights

  • The planned proof-of-concept study will examine seizure frequency, intensity, duration, nighttime seizures and sleep-related outcomes.
  • FDA lifted the clinical hold on Filana’s IND for simufilam.
  • Preparation for the TSC-related epilepsy proof-of-concept study included appointing a CRO, selecting trial locations and securing investigational drug supply.
  • The trial will assess safety, tolerability, pharmacokinetics and seizure- and sleep-related outcomes.

Filana Therapeutics, Inc. (NASDAQ: FLNA) is a biotechnology company. The FDA has lifted its clinical hold on Filana’s investigational new drug application for simufilam, allowing the planned proof-of-concept study in TSC-related epilepsy to advance.

Simufilam Study Moves Toward Patient Enrollment

Filana completed several preparation steps while the hold was in place. Those efforts included appointing a clinical research organization, selecting trial locations and recruiting potential investigators, while investigational drug Supply has been secured. Participants completing the blinded treatment period may take part in an extension study.

Data Intended to Guide Future Development

The trial is designed to examine safety, tolerability and pharmacokinetics, alongside seizure frequency, intensity, duration, nighttime seizures and sleep-related outcomes. Filana expects the resulting data to help determine the development route for simufilam in TSC-related epilepsy. The findings are also intended to inform the design of later studies involving younger patient populations.